<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title> &#187; General News</title>
	<atom:link href="http://pharmaexecnews.com/category/pharmaceuticals/general-news/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmaexecnews.com</link>
	<description></description>
	<lastBuildDate>Fri, 29 Apr 2011 14:00:12 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Medco in-line Profit Report Fails to Excite Market</title>
		<link>http://pharmaexecnews.com/biotechnology/medco-inline-profit-report-fails-excite-market/</link>
		<comments>http://pharmaexecnews.com/biotechnology/medco-inline-profit-report-fails-excite-market/#comments</comments>
		<pubDate>Thu, 03 Mar 2011 14:00:16 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Generics]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11243</guid>
		<description><![CDATA[Medco Health Solutions Inc&#8217;s (MHS.N) quarterly profit rose 11 percent on increased mail deliveries of generic drugs, but its shares fell as the report failed to excite investors.  The U.S. pharmacy benefit manager reported a fourth-quarter profit, excluding special items, that matched Wall Street&#8217;s target and it backed its 2011 forecast. Its shares fell 4.5 [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/medco-inline-profit-report-fails-excite-market/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>U.S. Court Clears Generic Allegra Sale</title>
		<link>http://pharmaexecnews.com/biotechnology/court-clears-generic-allegra-sale/</link>
		<comments>http://pharmaexecnews.com/biotechnology/court-clears-generic-allegra-sale/#comments</comments>
		<pubDate>Wed, 09 Feb 2011 08:00:07 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Generics]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[International News]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11146</guid>
		<description><![CDATA[India&#8217;s No.2 drugmaker Dr Reddy&#8217;s Laboratories Ltd said a U.S. district court has cleared the sale of its generic version of Sanofi-Aventis&#8217; allergy medicine Allegra D24, sending its shares up nearly 4 percent.  The U.S. District Court of New Jersey lifted an injunction passed last June against the Indian drugmaker from selling a copycat version [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/court-clears-generic-allegra-sale/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Copying Biotech Medicine Attracts More Drugmakers</title>
		<link>http://pharmaexecnews.com/biotechnology/copying-biotech-medicine-attracts-drugmakers/</link>
		<comments>http://pharmaexecnews.com/biotechnology/copying-biotech-medicine-attracts-drugmakers/#comments</comments>
		<pubDate>Tue, 01 Feb 2011 08:00:05 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Generics]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[cancer therapies]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11124</guid>
		<description><![CDATA[More drugmakers are seeing potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. The topic was at the forefront of plans discussed by several executives at this week&#8217;s JP Morgan healthcare conference in San Francisco. Kevin Sharer, chief executive officer at Amgen Inc, said the world&#8217;s largest [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/copying-biotech-medicine-attracts-drugmakers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer Bungles Tax-Fueled Champix Surge</title>
		<link>http://pharmaexecnews.com/biotechnology/pfizer-bungles-taxfueled-champix-surge/</link>
		<comments>http://pharmaexecnews.com/biotechnology/pfizer-bungles-taxfueled-champix-surge/#comments</comments>
		<pubDate>Mon, 17 Jan 2011 08:00:37 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11078</guid>
		<description><![CDATA[A new cigarette tax and a stop-smoking drug were a match made in Japan, and it might have been heaven if Pfizer ($PFE) hadn&#8217;t fumbled. The drugmaker, which sells its Chantix remedy as Champix in Japan, knew the higher tax was coming, advertised its drug heavily, and then failed to make enough to satisfy demand.

As [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/pfizer-bungles-taxfueled-champix-surge/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Co-pay Help Boosts Drugs, Scares Payers</title>
		<link>http://pharmaexecnews.com/biotechnology/copay-boosts-drugs-scares-payers/</link>
		<comments>http://pharmaexecnews.com/biotechnology/copay-boosts-drugs-scares-payers/#comments</comments>
		<pubDate>Fri, 07 Jan 2011 08:00:52 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Marketing]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11053</guid>
		<description><![CDATA[Coupons work. That&#8217;s what drugmakers have discovered from the co-pay assistance they&#8217;ve been offering to shore up demand for aging branded drugs (Pfizer&#8217;s statin Lipitor), create demand for new ones (such as Amgen&#8217;s bone drug Xgeva and Novartis&#8217; multiple sclerosis pill Gilenya), and insulate patients from big price increases (Jazz Pharmaceuticals&#8217; narcolepsy treatment Xyrem). As [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/copay-boosts-drugs-scares-payers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bacteria Provide Example of One of Nature&#8217;s First Immune Systems</title>
		<link>http://pharmaexecnews.com/biotechnology/bacteria-provide-natures-immune-systems/</link>
		<comments>http://pharmaexecnews.com/biotechnology/bacteria-provide-natures-immune-systems/#comments</comments>
		<pubDate>Tue, 04 Jan 2011 08:00:39 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Genomics]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[Virus]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[dna]]></category>
		<category><![CDATA[dna sequence]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11038</guid>
		<description><![CDATA[Studying how bacteria incorporate foreign DNA from invading viruses into their own regulatory processes, Thomas Wood, professor in the Artie McFerrin Department of Chemical Engineering at Texas  A&#38;M University, is uncovering the secrets of one of nature&#8217;s most primitive immune systems.

His findings, which appear in Nature Communications, shed light on how bacteria have throughout [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/bacteria-provide-natures-immune-systems/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Top 10 Phase III Failures of 2010</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/top-10-phase-iii-failures-2010/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/top-10-phase-iii-failures-2010/#comments</comments>
		<pubDate>Mon, 06 Dec 2010 08:00:19 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Companies]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Drug Trials]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10944</guid>
		<description><![CDATA[By Phase III, researchers are supposed to have a pretty good handle on just how promising an experimental therapy can be. There&#8217;s proof-of-concept data in the can and some clear indications of just how big a market a new drug can go on to capture.

But even if the odds of success are somewhat better, the [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/top-10-phase-iii-failures-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>L.H. and Merit Plan Medical Device Hirings</title>
		<link>http://pharmaexecnews.com/biotechnology/biomedical/lh-merit-plan-medical-device-hirings/</link>
		<comments>http://pharmaexecnews.com/biotechnology/biomedical/lh-merit-plan-medical-device-hirings/#comments</comments>
		<pubDate>Wed, 01 Dec 2010 08:00:15 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Devices and Technology]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10931</guid>
		<description><![CDATA[While the pharmaceutical industry is cutting jobs left and right, two medical device makers this week announced hiring plans. Utah-based Merit Medical Systems plans to hire 75 employees at its Virigna site and invest $1 million more in its business over the next 18 months. The company, founded in 1987, markets interventional and diagnostic procedures, [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/biomedical/lh-merit-plan-medical-device-hirings/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How is our Brain Wired for Attention?</title>
		<link>http://pharmaexecnews.com/biotechnology/biomedical/brain-wired-attention/</link>
		<comments>http://pharmaexecnews.com/biotechnology/biomedical/brain-wired-attention/#comments</comments>
		<pubDate>Mon, 15 Nov 2010 08:00:46 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10863</guid>
		<description><![CDATA[University of Utah (U of U) medical researchers have uncovered a wiring diagram that shows how the brain pays attention to visual, cognitive, sensory, and motor cues. The research provides a critical foundation for the study of abnormalities in attention that can be seen in many brain disorders such as autism, schizophrenia, and attention deficit [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/biomedical/brain-wired-attention/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Veterans with Bipolar Disorder May Have Increased Risk of Suicide</title>
		<link>http://pharmaexecnews.com/biotechnology/veterans-bipolar-disorder-increased-risk-suicide/</link>
		<comments>http://pharmaexecnews.com/biotechnology/veterans-bipolar-disorder-increased-risk-suicide/#comments</comments>
		<pubDate>Fri, 12 Nov 2010 08:00:01 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[depression]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10880</guid>
		<description><![CDATA[Veterans diagnosed with any psychiatric illness appear to have an elevated risk of suicide, and men with bipolar disorder and women with substance abuse disorders may have a particularly high risk, according to the Archives of General Psychiatry.

An estimated 90 percent to 98 percent of individuals who die from suicide meet criteria for at least [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/veterans-bipolar-disorder-increased-risk-suicide/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

